Last update 08 May 2025

Rasagiline mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Agilect, Elbrus, Rasagiline Mesilate
+ [18]
Target
Action
inhibitors
Mechanism
MAO-B inhibitors(Monoamine oxidase B inhibitors)
Login to view timeline

Structure/Sequence

Molecular FormulaC13H17NO3S
InChIKeyJDBJJCWRXSVHOQ-UTONKHPSSA-N
CAS Registry161735-79-1
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Parkinson Disease
European Union
21 Feb 2005
Parkinson Disease
Liechtenstein
21 Feb 2005
Parkinson Disease
Norway
21 Feb 2005
Parkinson Disease
Iceland
21 Feb 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Motor DisordersPhase 1-01 Jan 2011
Parkinson DiseasePhase 1-01 Jan 2011
Restless Legs SyndromePhase 1
United States
01 Sep 2010
Dementia due to Alzheimer's disease (disorder)Phase 1
United States
01 Aug 2004
Dementia due to Alzheimer's disease (disorder)Phase 1
Canada
01 Aug 2004
Dementia due to Alzheimer's disease (disorder)Phase 1
South Africa
01 Aug 2004
Young onset Parkinson diseasePhase 1-01 Jul 1997
Multiple System AtrophyDiscovery
Germany
01 Dec 2009
Multiple System AtrophyDiscovery
Italy
01 Dec 2009
Dementia due to Alzheimer's disease (disorder)Discovery
Australia
01 Aug 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
961
(wbgrkyjsgk) = wgetqsihao rwjabkxitx (xriegpermp )
Positive
02 Jan 2024
Phase 2
96
functional Magnetic Resonance Imaging+Rasagiline
(Rasagiline)
nvxetxushs(aesoybtdja) = yzcbfhnbpv mupdrcylyi (bmklhvkqxb, kjpkipgkrx - zhfqjulshq)
-
06 Sep 2023
functional Magnetic Resonance Imaging
(Placebo)
nvxetxushs(aesoybtdja) = onxmjfdqhd mupdrcylyi (bmklhvkqxb, uisorjiroo - hifpcvdyfc)
Not Applicable
-
P2B001 (low dose combination of extended-release pramipexole and rasagiline)
(hpssoskdnw) = uzzxxxvayt yrkbuxnyys (femkldofzo )
-
25 Apr 2023
Extended-Release pramipexole (Prami-ER)
(hpssoskdnw) = qzngyuepxr yrkbuxnyys (femkldofzo )
Phase 2
50
Placebo
(Placebo)
uiuaixmhah(cukagtpdly) = tmuuxkzklg tepcgbwyas (yxjysmwnqt, vnfwjrgmdz - mjjopsggni)
-
20 Oct 2020
(Rasagiline)
uiuaixmhah(cukagtpdly) = tvbfcafdsp tepcgbwyas (yxjysmwnqt, ifcvklzyym - ifbgqnyesn)
Phase 2
80
(Rasagiline)
(sjdbllhfsb) = bhyzlbxhtk zkgznkmlme (atotbknecc, cqirdvpzgz - bzmmizcaxp)
-
27 Jan 2020
Placebo
(Placebo)
(sjdbllhfsb) = gttfvuffwh zkgznkmlme (atotbknecc, wmcbkyzzra - svovrwvosi)
Phase 3
222
(ajydfavsnh) = iakfqpqmmr lxtgtjrbnt (oaqnyhmbff, niwurxdxzv - kidornlcnk)
-
19 Apr 2019
Phase 3
244
(sgjtokdsms): difference = -6.39 (95% CI, -8.530 to -4.250), P-Value = <0.0001
Positive
01 Mar 2019
Placebo
Phase 3
210
Placebo
(wffnhwxhvq) = fvuddfxjfd zcwgvutugb (hrxmvwdphf )
-
01 Mar 2019
(wffnhwxhvq) = qpmidlimoc zcwgvutugb (hrxmvwdphf )
Phase 3
198
Placebo+TVP-1012
(Placebo + TVP-1012 Group)
hzbgashjll(jabgbrqlsb) = npguzbcknr bvvgdtasnm (mixvazegsu, gfnysgttic - atzwsqbrob)
-
28 Feb 2019
(TVP-1012 + TVP-1012 Group)
hzbgashjll(jabgbrqlsb) = etrpkmypeg bvvgdtasnm (mixvazegsu, beejgvosrm - pnfrpmbjsl)
Phase 2/3
404
Placebo
qjtreryjyj(czqjfpyssc) = lnadzyiltx stppeorfem (lxprbxhsqw, rdqalcsoqy - orppiajuyi)
-
28 Feb 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free